312 related articles for article (PubMed ID: 33989303)
1. Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma.
Sloan SL; Renaldo KA; Long M; Chung JH; Courtney LE; Shilo K; Youssef Y; Schlotter S; Brown F; Klamer BG; Zhang X; Yilmaz AS; Ozer HG; Valli VE; Vaddi K; Scherle P; Alinari L; Kisseberth WC; Baiocchi RA
PLoS One; 2021; 16(5):e0250839. PubMed ID: 33989303
[TBL] [Abstract][Full Text] [Related]
2. Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing.
Chung J; Karkhanis V; Tae S; Yan F; Smith P; Ayers LW; Agostinelli C; Pileri S; Denis GV; Baiocchi RA; Sif S
J Biol Chem; 2013 Dec; 288(49):35534-47. PubMed ID: 24189068
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.
Alinari L; Mahasenan KV; Yan F; Karkhanis V; Chung JH; Smith EM; Quinion C; Smith PL; Kim L; Patton JT; Lapalombella R; Yu B; Wu Y; Roy S; De Leo A; Pileri S; Agostinelli C; Ayers L; Bradner JE; Chen-Kiang S; Elemento O; Motiwala T; Majumder S; Byrd JC; Jacob S; Sif S; Li C; Baiocchi RA
Blood; 2015 Apr; 125(16):2530-43. PubMed ID: 25742700
[TBL] [Abstract][Full Text] [Related]
4. Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3.
Zhang B; Dong S; Zhu R; Hu C; Hou J; Li Y; Zhao Q; Shao X; Bu Q; Li H; Wu Y; Cen X; Zhao Y
Oncotarget; 2015 Sep; 6(26):22799-811. PubMed ID: 26078354
[TBL] [Abstract][Full Text] [Related]
5. Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery.
Wang Y; Hu W; Yuan Y
J Med Chem; 2018 Nov; 61(21):9429-9441. PubMed ID: 29870258
[TBL] [Abstract][Full Text] [Related]
6. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
[TBL] [Abstract][Full Text] [Related]
7. Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.
Yan F; Alinari L; Lustberg ME; Martin LK; Cordero-Nieves HM; Banasavadi-Siddegowda Y; Virk S; Barnholtz-Sloan J; Bell EH; Wojton J; Jacob NK; Chakravarti A; Nowicki MO; Wu X; Lapalombella R; Datta J; Yu B; Gordon K; Haseley A; Patton JT; Smith PL; Ryu J; Zhang X; Mo X; Marcucci G; Nuovo G; Kwon CH; Byrd JC; Chiocca EA; Li C; Sif S; Jacob S; Lawler S; Kaur B; Baiocchi RA
Cancer Res; 2014 Mar; 74(6):1752-65. PubMed ID: 24453002
[TBL] [Abstract][Full Text] [Related]
8. Targeting protein arginine methyltransferase 5 in cancers: Roles, inhibitors and mechanisms.
Chen Y; Shao X; Zhao X; Ji Y; Liu X; Li P; Zhang M; Wang Q
Biomed Pharmacother; 2021 Dec; 144():112252. PubMed ID: 34619493
[TBL] [Abstract][Full Text] [Related]
9. Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors.
Zhu K; Song JL; Tao HR; Cheng ZQ; Jiang CS; Zhang H
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3693-3699. PubMed ID: 30366617
[TBL] [Abstract][Full Text] [Related]
10. Targeting protein arginine methyltransferase 5 in disease.
Richters A
Future Med Chem; 2017 Nov; 9(17):2081-2098. PubMed ID: 29076773
[TBL] [Abstract][Full Text] [Related]
11. PRMT5-mediated histone arginine methylation antagonizes transcriptional repression by polycomb complex PRC2.
Liu F; Xu Y; Lu X; Hamard PJ; Karl DL; Man N; Mookhtiar AK; Martinez C; Lossos IS; Sun J; Nimer SD
Nucleic Acids Res; 2020 Apr; 48(6):2956-2968. PubMed ID: 32025719
[TBL] [Abstract][Full Text] [Related]
12. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.
Yang L; Ma DW; Cao YP; Li DZ; Zhou X; Feng JF; Bao J
Theranostics; 2021; 11(8):3742-3759. PubMed ID: 33664859
[No Abstract] [Full Text] [Related]
13. Protein arginine methyltransferase 5 catalyzes substrate dimethylation in a distributive fashion.
Wang M; Fuhrmann J; Thompson PR
Biochemistry; 2014 Dec; 53(50):7884-92. PubMed ID: 25485739
[TBL] [Abstract][Full Text] [Related]
14. Arginine methyltransferase inhibitor 1 inhibits gastric cancer by downregulating eIF4E and targeting PRMT5.
Zhang B; Zhang S; Zhu L; Chen X; Zhao Y; Chao L; Zhou J; Wang X; Zhang X; Ma N
Toxicol Appl Pharmacol; 2017 Dec; 336():1-7. PubMed ID: 28987382
[TBL] [Abstract][Full Text] [Related]
15. PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD).
Ratovitski T; Arbez N; Stewart JC; Chighladze E; Ross CA
Cell Cycle; 2015; 14(11):1716-29. PubMed ID: 25927346
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic control via allosteric regulation of mammalian protein arginine methyltransferases.
Jain K; Jin CY; Clarke SG
Proc Natl Acad Sci U S A; 2017 Sep; 114(38):10101-10106. PubMed ID: 28874563
[TBL] [Abstract][Full Text] [Related]
17. PRMT5 inhibition promotes osteogenic differentiation of mesenchymal stromal cells and represses basal interferon stimulated gene expression.
Kota SK; Roening C; Patel N; Kota SB; Baron R
Bone; 2018 Dec; 117():37-46. PubMed ID: 30189247
[TBL] [Abstract][Full Text] [Related]
18. Rational Design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity.
Zhu K; Shao J; Tao H; Yan X; Luo C; Zhang H; Duan W
J Comput Aided Mol Des; 2019 Aug; 33(8):775-785. PubMed ID: 31312965
[TBL] [Abstract][Full Text] [Related]
19. CARM1-mediated methylation of protein arginine methyltransferase 5 represses human γ-globin gene expression in erythroleukemia cells.
Nie M; Wang Y; Guo C; Li X; Wang Y; Deng Y; Yao B; Gui T; Ma C; Liu M; Wang P; Wang R; Tan R; Fang M; Chen B; He Y; Huang DCS; Ju J; Zhao Q
J Biol Chem; 2018 Nov; 293(45):17454-17463. PubMed ID: 30257864
[TBL] [Abstract][Full Text] [Related]
20. Resistance to PRMT5-targeted therapy in mantle cell lymphoma.
Long ME; Koirala S; Sloan S; Brown-Burke F; Weigel C; Villagomez L; Corps K; Sharma A; Hout I; Harper M; Helmig-Mason J; Tallada S; Chen Z; Scherle P; Vaddi K; Chen-Kiang S; Di Liberto M; Meydan C; Foox J; Butler D; Mason C; Alinari L; Blaser BW; Baiocchi R
Blood Adv; 2024 Jan; 8(1):150-163. PubMed ID: 37782774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
